Clinical Trial Update: Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

View source ↗

Summary

An exploratory clinical trial evaluating a 14-day bismuth-containing quadruple therapy guided by drug susceptibility testing for extremely refractory Helicobact…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• bismuth-containing quadruple therapy (PPI + bismuth + metronidazole + tetracycline)

Snippet

Sponsor: Xiuli Zuo | Conditions: HELICOBACTER PYLORI INFECTIONS | Status: NOT_YET_RECRUITING